retatrutide phase 2 trial type 2 diabetes weight loss 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Lilly's triple agonist delivers up

Let's call them out so you don't have to learn the hard way

"Americans should be confident that the prescription drugs they take are safe," FDA Commissioner Marty Makary, M.D., M.P.H., said in an agency statement

Hydration Tips to Alleviate Discomfort Drink fluids between meals rather than with meals to prevent your stomach from becoming overly full

Interestingly, the metabolic improvements from significant weight loss (24.2% on average) are typically associated with improvements in fatty liver disease indicators rather than liver stress

Li H, Guglielmetti C, Sei YJ, Zilberter M, Le Page LM, Shields L, Yang J, Nguyen K, Tiret B, Gao X, Bennett N, Lo I, Dayton TL, Kampmann M, Huang Y, Rathmell JC, Vander Heiden M, Chaumeil MM, Nakamura K (2023a) Neurons require glucose uptake and glycolysis in vivo